Investigational Seladelpar Demonstrates Significant Improvem

- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months -


- Reduction in Patient-Reported Pruritus was...

Related Keywords

United Kingdom , Washington , United States , Foster City , California , Merdad Parsey , Gilead Sciences In Liver Disease , Gilead Sciences Inc , Regulatory Agency , Nasdaq , Gilead Company , Exchange Commission , Cymabay Therapeutics Inc , Drug Administration , University Of Miami , European Medicines Agency , Gilead Sciences , Cymabay Therapeutics , Presidential Plenary , Digestive Disease , Cynthia Levy , Chief Medical Officer , New Drug Application , Child Pugh , United Kingdom Medicines , Primary Biliary Cholangitis , Interim Results , Bay Therapeutics , Private Securities Litigation Reform Act , Quarterly Report , Liver Disease ,